Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annovis Bio Inc (NY: ANVS )

12.74 +0.86 (+7.24%)
Official Closing Price Updated: 6:30 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Annovis Bio Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
From Glancy Prongay & Murray LLP
Via Business Wire
ANNOVIS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Annovis Bio, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
ANVS ALERT: Investors With Substantial Losses Have Opportunity to Lead the Annovis Bio, Inc. Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Annovis Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline – ANVS
From The Rosen Law Firm, P.A.
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
From Law Offices of Howard G. Smith
Via Business Wire
ANVS CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Annovis Bio, Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
ANNOVIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Annovis Bio, Inc. on Behalf of Annovis Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Annovis Bio, Inc.
From Kirby McInerney LLP
Via Business Wire
Annovis Bio to Present Data at Alzheimer's Association International Conference 2021 Highlighting Positive Clinical Outcomes from Its Two Phase 2a Trials
Berwyn, Pennsylvania--(Newsfile Corp. - July 2, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Annovis Bio CEO Wins 2021 PACT Enterprise Award for Life Sciences and Healthcare CEO
Berwyn, Pennsylvania--(Newsfile Corp. - July 1, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Annovis Bio CEO Selected as a Finalist in the 2021 PACT Enterprise Awards
Berwyn, Pennsylvania--(Newsfile Corp. - June 24, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Annovis Bio to Present at 2021 BIO Digital
Berwyn, Pennsylvania--(Newsfile Corp. - June 10, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Annovis Bio Expands Potential Application of ANVS401 to Infectious Diseases with New Preclinical Study
Berwyn, Pennsylvania--(Newsfile Corp. - June 8, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a... 
Via Newsfile
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Annovis Bio to Present at Jefferies Virtual Healthcare Conference 2021
Berwyn, Pennsylvania--(Newsfile Corp. - June 3, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Annovis Bio's ANVS401 Improves Speed and Accuracy in Alzheimer's and in Parkinson's Patients
Berwyn, Pennsylvania--(Newsfile Corp. - June 1, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's... 
Via Newsfile
Annovis Bio Engages Global Executive Search Leader Spencer Stuart to Expand its Board and Management Team
Berwyn, Pennsylvania--(Newsfile Corp. - May 28, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Exposures Product Safety
Annovis Bio, Inc. Announces Closing of $50 Million Public Offering
Berwyn, Pennsylvania--(Newsfile Corp. - May 27, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Annovis Bio, Inc. Announces Pricing of Public Offering
Berwyn, Pennsylvania--(Newsfile Corp. - May 23, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock
Berwyn, Pennsylvania--(Newsfile Corp. - May 21, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer's Disease - Patients' Cognition Improved 3.3 Points on ADAS-Cog11
Berwyn, Pennsylvania--(Newsfile Corp. - May 21, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing... 
Via Newsfile
Exposures Product Safety
Annovis Bio to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and Hosted by M-Vest on May 26th, 2021
Berwyn, Pennsylvania--(Newsfile Corp. - May 20, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing... 
Via Newsfile
Annovis Bio Announces Positive Phase 2 Data: ANVS401 Significantly Lowers Inflammatory Markers in Parkinson's Patients
Berwyn, Pennsylvania--(Newsfile Corp. - May 19, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing... 
Via Newsfile
Exposures Product Safety
Annovis Bio Appoints Accomplished Neuroscientist, Dr. Cheng Fang as VP of Research
Berwyn, Pennsylvania--(Newsfile Corp. - May 18, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company... 
Via Newsfile
Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer's Disease in Persons with Down Syndrome
Berwyn, Pennsylvania--(Newsfile Corp. - May 13, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing... 
Via Newsfile
Exposures Product Safety
Annovis Bio to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021
Berwyn, Pennsylvania--(Newsfile Corp. - May 11, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing... 
Via Newsfile
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.